Dent, R., Cortés, J., Park, Y. H., Muñoz-Couselo, E., Kim, S., Sohn, J., . . . Schmid, P. (2025). Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: Exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study. Breast Cancer Research, 27(1), 1-12. https://doi.org/10.1186/s13058-024-01946-y

Dent, Rebecca, et al. "Molecular Determinants of Response to Neoadjuvant Pembrolizumab Plus Chemotherapy in Patients with High-risk, Early-stage, Triple-negative Breast Cancer: Exploratory Analysis of the Open-label, Multicohort Phase 1b KEYNOTE-173 Study." Breast Cancer Research 27, no. 1 (2025): 1-12. https://doi.org/10.1186/s13058-024-01946-y.

Dent, Rebecca, et al. "Molecular Determinants of Response to Neoadjuvant Pembrolizumab Plus Chemotherapy in Patients with High-risk, Early-stage, Triple-negative Breast Cancer: Exploratory Analysis of the Open-label, Multicohort Phase 1b KEYNOTE-173 Study." Breast Cancer Research, vol. 27, no. 1, 2025, pp. 1-12, https://doi.org/10.1186/s13058-024-01946-y.